News
VTVT
18.82
+1.29%
0.24
Weekly Report: what happened at VTVT last week (0407-0411)?
Weekly Report · 2d ago
vTv Therapeutics Appoints Barry Brown as Interim CFO
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Walmart, Ford Motor, Starbucks
Reuters · 04/09 18:26
BUZZ-U.S. STOCKS ON THE MOVE-Delta Air Lines, U.S Steel Corp, Lincoln National
Reuters · 04/09 13:16
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 04/09 12:18
BUZZ-H.C. Wainwright starts vTv Therapeutics with 'buy' as diabetes drug study set to resume
Reuters · 04/09 11:59
vTv Therapeutics Initiated at Buy by HC Wainwright & Co.
Dow Jones · 04/09 11:33
vTv Therapeutics Price Target Announced at $36.00/Share by HC Wainwright & Co.
Dow Jones · 04/09 11:33
HC Wainwright & Co. Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $36
Benzinga · 04/09 11:23
VTV THERAPEUTICS INC <VTVT.O>: H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $36
Reuters · 04/09 11:14
Promising Potential of vTv Therapeutics’ Cadisegliatin in Addressing Unmet Needs in Type 1 Diabetes
TipRanks · 04/09 10:16
vTv Therapeutics initiated with a Buy at H.C. Wainwright
TipRanks · 04/09 10:10
Weekly Report: what happened at VTVT last week (0331-0404)?
Weekly Report · 04/07 12:13
vTv Therapeutics Resumes Phase 3 Trial for Cadisegliatin
TipRanks · 03/31 21:02
Weekly Report: what happened at VTVT last week (0324-0328)?
Weekly Report · 03/31 12:29
Weekly Report: what happened at VTVT last week (0317-0321)?
Weekly Report · 03/24 12:12
Alliance Global Partners Sticks to Its Buy Rating for vTv Therapeutics (VTVT)
TipRanks · 03/21 11:35
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
NASDAQ · 03/21 08:46
vTv Therapeutics GAAP EPS of -$0.55, revenue of $0.02M
Seeking Alpha · 03/21 05:10
vTv Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 03/20 22:04
More
Webull provides a variety of real-time VTVT stock news. You can receive the latest news about Vtv Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About VTVT
More
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.